GlassScriptPhysician profile
David G Boland
NPI 1235123886
$6,476.19
in general payments reported to CMS, 2019-2025
27 companies · $646 in 2025
The $646 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $193 · 2021: $782 · 2022: $1,357 · 2023: $722 · 2024: $2,165 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,749 · Travel and Lodging: $784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,749.01 |
| Travel and Lodging | $784.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,403.05 | 2019-2025 | Sapien 3 Ultra Resilia, Pascal, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Cordis US Corp. | $1,010.08 | 2024 | Angioguard, Precise Pro Rx |
| Abiomed | $511.88 | 2019-2025 | Impella |
| Medtronic, INC. | $492.21 | 2021-2024 | Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $384.09 | 2020-2025 | |
| Medtronic Vascular, INC. | $380.38 | 2019-2020 | |
| Shockwave Medical, INC | $283.81 | 2020-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $139.45 | 2022-2025 | Repatha |
| Boston Scientific Corporation | $122.44 | 2019-2023 | Watchman Access System |
| Merck Sharp & Dohme LLC | $122.29 | 2021-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $116.60 | 2019-2023 | Camzyos |
| Pfizer INC. | $88.90 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.07 | 2022-2024 | Jardiance |
| Chiesi USA, INC. | $45.27 | 2019 | |
| Novo Nordisk INC | $43.99 | 2023-2024 | Ozempic, Rybelsus |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $40.17 | 2019 | |
| Esperion Therapeutics, INC. | $32.77 | 2021 | |
| Cardinal Health 200 LLC | $32.62 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $25.66 | 2023 | Opsumit, Uptravi |
| Philips North America LLC | $22.56 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.70 | 2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $17.03 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.84 | 2023 | |
| Atricure, INC. | $14.61 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $14.41 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $14.15 | 2021 | |
| Terumo Medical Corporation | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Boland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.